Merck & Co. (MRK)
(Real Time Quote from BATS)
$129.48 USD
-0.72 (-0.55%)
Updated Jun 13, 2024 03:48 PM ET
After-Market: $129.37 -0.11 (-0.08%) 4:06 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
Merck & Co., Inc. [MRK]
Reports for Purchase
Showing records 381 - 396 ( 396 total )
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter EPS Ahead of Expectations. Less Cost Cutting Likely Going Forward.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Second Quarter Pro-forma Revenue Down 1%. More Revenue Headwinds in the 2010 Second Half.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter Figures Reflect a Partial Quarter of Results from Schering-Plough
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S